Regulation of Human Embryonic Stem Cells in Europe

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The benefit of developing new health technologies cannot be doubted, but divorcing this benefit from the moral controversies which surround innovations, such as stem cell therapies, is far from easy. This chapter considers how permissive and cohesive the regulatory landscape, applicable to human stem cells (particularly embryonic stem cells), in Europe is by focusing in detail upon the most controversial areas of patenting and licensing, broadly compared to research funding and specific European Union (EU) regulation. The analysis begins by gently introducing the science behind current innovations. Adopting a legal analysis, the current situation in Europe is identified in terms of patenting: pluripotent stem cells, totipotent cells, induced pluripotent and protein-induced pluripotent stem cells (and for completeness multipotent stem cells), their derivative products, and the processes which create them. This enables the impacts of patenting to be assessed, which identifies that the European patent system and EU approaches are far less restrictive than they appear. This creates a risk of patenting law being misinterpreted as conveying a restrictive moral approach to the technology, rather than the permissive legal approach to patenting innovation that it is. Comparison with the overarching regulation identifies that, despite the broad definition of human embryos adopted by the EU in determining patenting, there is a cohesive approach to regulating human embryonic stem cells. This is structured to maximize the choice of individual Member States in determining how permissively or restrictively they wish to regulate stem cell technology.
Original languageEnglish
Title of host publicationLegal and Forensic Medicine
EditorsProf Roy G. Beran
PublisherSpringer Berlin Heidelberg
Pages1561-1597
Number of pages37
ISBN (Electronic)9783642323386
ISBN (Print)9783642323379
DOIs
Publication statusPublished - 1 Jul 2013
Externally publishedYes

Fingerprint

innovation
regulation
patent system
embryo
funding
Law
science
health

Cite this

Warren-Jones, A. (2013). Regulation of Human Embryonic Stem Cells in Europe. In P. R. G. Beran (Ed.), Legal and Forensic Medicine (pp. 1561-1597). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-32338-6_111
Warren-Jones, Amanda. / Regulation of Human Embryonic Stem Cells in Europe. Legal and Forensic Medicine. editor / Prof Roy G. Beran. Springer Berlin Heidelberg, 2013. pp. 1561-1597
@inbook{c251ae894ced4f409ca84fd1b2f7235f,
title = "Regulation of Human Embryonic Stem Cells in Europe",
abstract = "The benefit of developing new health technologies cannot be doubted, but divorcing this benefit from the moral controversies which surround innovations, such as stem cell therapies, is far from easy. This chapter considers how permissive and cohesive the regulatory landscape, applicable to human stem cells (particularly embryonic stem cells), in Europe is by focusing in detail upon the most controversial areas of patenting and licensing, broadly compared to research funding and specific European Union (EU) regulation. The analysis begins by gently introducing the science behind current innovations. Adopting a legal analysis, the current situation in Europe is identified in terms of patenting: pluripotent stem cells, totipotent cells, induced pluripotent and protein-induced pluripotent stem cells (and for completeness multipotent stem cells), their derivative products, and the processes which create them. This enables the impacts of patenting to be assessed, which identifies that the European patent system and EU approaches are far less restrictive than they appear. This creates a risk of patenting law being misinterpreted as conveying a restrictive moral approach to the technology, rather than the permissive legal approach to patenting innovation that it is. Comparison with the overarching regulation identifies that, despite the broad definition of human embryos adopted by the EU in determining patenting, there is a cohesive approach to regulating human embryonic stem cells. This is structured to maximize the choice of individual Member States in determining how permissively or restrictively they wish to regulate stem cell technology.",
keywords = "stem cell, European Union, pluripotent stem cell, human embryo, preimplantation genetic diagnosis",
author = "Amanda Warren-Jones",
year = "2013",
month = "7",
day = "1",
doi = "10.1007/978-3-642-32338-6_111",
language = "English",
isbn = "9783642323379",
pages = "1561--1597",
editor = "Beran, {Prof Roy G.}",
booktitle = "Legal and Forensic Medicine",
publisher = "Springer Berlin Heidelberg",

}

Warren-Jones, A 2013, Regulation of Human Embryonic Stem Cells in Europe. in PRG Beran (ed.), Legal and Forensic Medicine. Springer Berlin Heidelberg, pp. 1561-1597. https://doi.org/10.1007/978-3-642-32338-6_111

Regulation of Human Embryonic Stem Cells in Europe. / Warren-Jones, Amanda.

Legal and Forensic Medicine. ed. / Prof Roy G. Beran. Springer Berlin Heidelberg, 2013. p. 1561-1597.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Regulation of Human Embryonic Stem Cells in Europe

AU - Warren-Jones, Amanda

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The benefit of developing new health technologies cannot be doubted, but divorcing this benefit from the moral controversies which surround innovations, such as stem cell therapies, is far from easy. This chapter considers how permissive and cohesive the regulatory landscape, applicable to human stem cells (particularly embryonic stem cells), in Europe is by focusing in detail upon the most controversial areas of patenting and licensing, broadly compared to research funding and specific European Union (EU) regulation. The analysis begins by gently introducing the science behind current innovations. Adopting a legal analysis, the current situation in Europe is identified in terms of patenting: pluripotent stem cells, totipotent cells, induced pluripotent and protein-induced pluripotent stem cells (and for completeness multipotent stem cells), their derivative products, and the processes which create them. This enables the impacts of patenting to be assessed, which identifies that the European patent system and EU approaches are far less restrictive than they appear. This creates a risk of patenting law being misinterpreted as conveying a restrictive moral approach to the technology, rather than the permissive legal approach to patenting innovation that it is. Comparison with the overarching regulation identifies that, despite the broad definition of human embryos adopted by the EU in determining patenting, there is a cohesive approach to regulating human embryonic stem cells. This is structured to maximize the choice of individual Member States in determining how permissively or restrictively they wish to regulate stem cell technology.

AB - The benefit of developing new health technologies cannot be doubted, but divorcing this benefit from the moral controversies which surround innovations, such as stem cell therapies, is far from easy. This chapter considers how permissive and cohesive the regulatory landscape, applicable to human stem cells (particularly embryonic stem cells), in Europe is by focusing in detail upon the most controversial areas of patenting and licensing, broadly compared to research funding and specific European Union (EU) regulation. The analysis begins by gently introducing the science behind current innovations. Adopting a legal analysis, the current situation in Europe is identified in terms of patenting: pluripotent stem cells, totipotent cells, induced pluripotent and protein-induced pluripotent stem cells (and for completeness multipotent stem cells), their derivative products, and the processes which create them. This enables the impacts of patenting to be assessed, which identifies that the European patent system and EU approaches are far less restrictive than they appear. This creates a risk of patenting law being misinterpreted as conveying a restrictive moral approach to the technology, rather than the permissive legal approach to patenting innovation that it is. Comparison with the overarching regulation identifies that, despite the broad definition of human embryos adopted by the EU in determining patenting, there is a cohesive approach to regulating human embryonic stem cells. This is structured to maximize the choice of individual Member States in determining how permissively or restrictively they wish to regulate stem cell technology.

KW - stem cell

KW - European Union

KW - pluripotent stem cell

KW - human embryo

KW - preimplantation genetic diagnosis

UR - https://www.springer.com/gp/book/9783642323379#otherversion=9783642323393

U2 - 10.1007/978-3-642-32338-6_111

DO - 10.1007/978-3-642-32338-6_111

M3 - Chapter

SN - 9783642323379

SP - 1561

EP - 1597

BT - Legal and Forensic Medicine

A2 - Beran, Prof Roy G.

PB - Springer Berlin Heidelberg

ER -

Warren-Jones A. Regulation of Human Embryonic Stem Cells in Europe. In Beran PRG, editor, Legal and Forensic Medicine. Springer Berlin Heidelberg. 2013. p. 1561-1597 https://doi.org/10.1007/978-3-642-32338-6_111